Both CD14+ monocytes from synovial fluid and CD68+ synovial tissue macrophages from RA patients with active disease have an activated phenotype (70–73) and produce pro-inflammatory cytokines, including TNF, IL-6, and GM-CSF that are targets for current successful RA therapies (74–76). This evidence concerns the gene TNF and rheumatoid arthritis.